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Abstract
Objective
Mutations in CD59 cause CIDP-like polyneuropathy in children with inherited chronic hemo-
lysis. We hypothesized that mutations in CD59 might be found in a subset of sporadic CIDP
patients.
Methods
35 patients from two centers, fulfilling the EFNS/PNS diagnostic criteria for CIDP were
included. CD59 coding region was amplified by PCR and Sanger sequenced.
Results
One rare variant was detected in a patient which resulted in a synonymous change and pre-
dicted to be neutral. Pathogenic variants were absent in our cohort.
Interpretation
Our pilot study suggests that mutations in CD59 are absent in adult-onset sporadic CIDP.
Introduction
Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a rare and heteroge-
neous neurological disorder that is diagnosed according to clinical and electrophysiological
diagnostic criteria. Its pathogenesis is largely unknown although an autoimmune origin is
PLOS ONE | https://doi.org/10.1371/journal.pone.0212647 February 22, 2019 1 / 6
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPEN ACCESS
Citation: Duchateau L, Martı´n-Aguilar L, Lleixà C,
Cortese A, Dols-Icardo O, Cervera-Carles L, et al.
(2019) Absence of pathogenic mutations in CD59
in chronic inflammatory demyelinating
polyradiculoneuropathy. PLoS ONE 14(2):
e0212647. https://doi.org/10.1371/journal.
pone.0212647
Editor: Alfred S. Lewin, University of Florida,
UNITED STATES
Received: November 5, 2018
Accepted: February 6, 2019
Published: February 22, 2019
Copyright: © 2019 Duchateau et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: Data cannot be
shared publicly because they include pseudo
anonymized clinical and epidemiological
information that could lead to patient identification,
considering the rarity of this disease. This
restriction is imposed by the Ethics’ Committee of
Hospital de la Santa Creu i Sant Pau. Specific parts
of the dataset are available under request
(malonsoma@santpau.cat).
widely accepted. The response to immunomodulatory therapy, including intravenous immu-
noglobulins (IVIg), glucocorticosteroids and plasma exchange, supports the autoimmune
hypothesis and the role of humoral factors, including autoantibodies, in its pathogenesis. Tra-
ditional CIDP pathogenic models describe the presence of combined cell-mediated and
humoral immunity that result in an aberrant immune response targeting myelinated fibres of
peripheral nerves [1]. However, the relative contribution of each component of the immune
response is unknown. The recent discovery of disease-specific antibodies, such as anti-neuro-
fascin 155 (anti-NF155), anti-contactin-1, anti-contactin-associated protein 1 and nodal neu-
rofascin antibodies, that are only present in 5–10% of patients [2–4], suggests the existence of
small but homogeneous subgroups of CIDP patients in which specific effector mechanisms
drive the disease. This model may explain better patient heterogeneity within the CIDP spec-
trum. Indeed the clinical, pathological and genetic heterogeneity disappears when patients are
stratified according to highly specific biomarkers, such as autoantibodies [5–7]. The recent
description of a significantly increased frequency of the HLA DRB1�15 allele in anti-NF155
antibody-positive patients in comparison with those anti-NF155 antibody-negative, an associ-
ation that remained hidden before the description of these antibodies, supports this hypothesis
[7]. These findings strongly suggest that, even though CIDP has an autoimmune pathogenesis,
genetic factors could be essential in the development of CIDP in a subset of patients. Unfortu-
nately, due to the rarity of the disease and the difficulty to recruit biologically homogeneous
series of patients, research on the genetic factors related to CIDP is scarce [8].
A non-synonymous homozygous mutation (p.Cys58Tyr) in CD59, a complement inhibitor
present in the surface of red blood cells, was discovered in five Jewish children from North-
Africa with chronic haemolysis and childhood relapsing immune-mediated polyneuropathy
[9]. Interestingly, their symptoms were very similar to those of patients suffering from CIDP
and the children had a partial response to IVIg and corticosteroid treatment.
We then hypothesized that de novo mutations in CD59 might account for a fraction of
adult-onset sporadic CIDP patients. With the aim of evaluating the possible role of CD59 in
CIDP, its coding region was fully sequenced in a homogeneous series of patients who did not
present detectable anti-NF155, anti-contactin-1, NF140/186 or CASPR1 autoantibodies.
Material and methods
Patients, samples, protocol approvals and patient consents
Patients diagnosed with CIDP according to the European Federation of Neurological Socie-
ties/Peripheral Nerve Society (EFNS/PNS) diagnostic criteria[10] provided written informed
consent to participate and were included in the study according to a protocol approved by the
Institution’s Ethics’ Committee of Hospital de la Santa Creu i Sant Pau. Patients were recruited
between January and December of 2016. Whole blood was drawn in EDTA tubes and DNA
extracted following standard protocols and stored until needed.
Genetic studies
The entire coding region of CD59 gene (transcript variant CD59-211 ENST00000642928.1)
was amplified by polymerase chain reaction (PCR) and Sanger sequenced on an ABI 3100
automatic sequencer (Applied Biosystems, Foster City, CA, USA).
Resulting electropherograms were visually analyzed using Sequencher software (Gene
Codes Corp. Ann Arbor, MI, USA). Primer pair sequences and PCR conditions are available
under request. In silico evaluation of potential deleterious effects of CD59 genetic variants was
performed with the CADD-score (http://cadd.gs.washington.edu/), Mutation Taster (http://
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www.mutationtaster.org/), SIFT (http://sift.jcvi.org/), and Human Splicing Finder tool (http://
www.umd.be/HSF3/index.html).
Results
A total of 35 patients (57% male, mean age at inclusion 61 years old) were included in the
study. Direct sequencing of all coding exons of CD59 was performed. Only one variant was
detected in one patient (Fig 1), a heterozygous guanine to alanine substitution (c.18G>A)
which resulted in the synonymous change rs111771149 (p.Gly6Gly). According to the genome
aggregation database (http://gnomad.broadinstitute.org/) this is a rare variant with an allele
frequency of 0.003 in ExAC database and 0.001899 in gnomAD database in non-Finnish Euro-
peans. In silico analysis of possible damaging consequences did not reveal any potential delete-
rious effect related to this genetic variant. The previously reported pathogenic p.Cys58Tyr
mutation was not present in our patient cohort.
Discussion
Our pilot study failed to identify functionally-relevant CD59 mutations in sporadic adult-
onset CIDP patients suggesting that genetic dysfunction of CD59 is not a frequent cause of
CIDP. A rare variant was found in one patient but was predicted to be functionally irrelevant.
CD59 (protectin) encodes a glycosylphosphatidylinositol (GPI)-anchored cell surface mem-
brane glycoprotein, which inhibits polymerization of complement molecule C9, the final step
of membrane attack complex (MAC) formation, to protect host cells from complement-medi-
ated lysis [9].
Loss of function of CD59 thus might make cells, such as Schwann cells, susceptible to
MAC-mediated lysis, possibly causing demyelination. In fact, complement deposits have been
observed in areas of demyelination in sural nerve biopsies of patients with CIDP [11,12]. Also,
CD59-deficient mice show MAC deposits in the perivascular tissue in the areas of demyelin-
ation, and are more susceptible to experimental autoimmune encephalomyelitis, inflammation
and axonal loss than wild type mice [13].
Congenital CD59 deficiency is an extremely rare and recently described disease character-
ized by hemolysis, recurrent ischemic strokes and relapsing immune-mediated polyneuropa-
thy [9,14].
After the description of the pathogenic CD59 mutation p.Cys58Tyr[9], other CD59 muta-
tions have been described. In 2015, a homozygous missense mutation (p.Asp49Val) was
reported to be pathogenic in three Turkish patients from a two-generation family with
immune-mediated peripheral neuropathy, chronic hemolysis and strokes [15]. Recently, a
Fig 1. Electropherogram of the variant c.18G>A (above) and without the variant (down).
https://doi.org/10.1371/journal.pone.0212647.g001
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homozygous frameshift deletion in CD59 (c.146delA, pAsp49Valfs�31) has been described in a
7-year-old girl with a demyelinating polyneuropathy and cerebral vasculopathy [14].
These severe symptoms support the importance of CD59 as an essential complement regu-
latory protein for protection of hematopoietic and Schwann cells against complement attack.
Acquired CD59 deficiency is well known in paroxysmal nocturnal hemoglobinuria (PNH),
where a clonal defect in GPI biosynthesis confined to the hematological system, results in
hemolysis and prothrombotic tendency[16]. Eculizumab, a C5 inhibitor, is a treatment
approved for PNH [17]. Therefore, treatment with eculizumab proved also effective in congen-
ital CD59 deficiency; with a marked clinical improvement of these children, a reduction of
hospitalizations and a reduction of IVIg and steroid doses [18]. Detection of CD59 mutations
would have provided a novel therapeutic target in sporadic CIDP patients.
To our knowledge, this is the first genetic study aimed at identifying CD59 alterations in
CIDP. However, a study investigated the presence of antibodies targeting the complement
inhibitors CD46, CD55 and CD59 and found no association of these antibodies with inflam-
matory neuropathies [19].
In summary, our results suggest that CD59 mutations are not present in sporadic CIDP
patients. We did not study somatic mutations restricted to nerve (mosaicism) or to regulatory
regions of CD59 and, thus, the possibility that CD59 dysfunction plays a role in some CIDP
patients has not been completely ruled out. Caution should be made in interpreting our data,
since we used a limited series of patients and, therefore, we cannot exclude that rare CD59
mutations are the cause of sporadic CIDP. However, our study suggests that these mutations
are not a frequent cause of CIDP. Since CIDP is a very rare disease and single-center case series
are consequently small, further genetic and immunologic studies in larger, collaborative, CIDP
cohorts [20] are needed to unravel the genetic basis of CIDP, improve pathogenetic models
and find clinically useful biomarkers.
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